Unknown

Dataset Information

0

Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.


ABSTRACT: Endothelin 1 (ET-1) contributes to chronic kidney disease (CKD) development and progression, and endothelin receptor antagonists are being investigated as a novel therapy for CKD. The proET-1 peptides, endothelin-like domain peptide (ELDP) and C-terminal pro-ET-1 (CT-proET-1), are both potential biomarkers of CKD and response to therapy with endothelin antagonists.We assessed plasma and urine ELDP and plasma CT-proET-1 in CKD patients with minimal comorbidity. Next, in a randomized double-blind crossover study of 27 subjects with proteinuric CKD, we examined the effects of 6 weeks of treatment with placebo, sitaxentan (endothelin A antagonist), and nifedipine on these peptides alongside the primary end points of proteinuria, blood pressure, and arterial stiffness. Plasma ELDP and CT-proET-1 increased with CKD stage (both P<0.0001), correlating inversely with estimated glomerular filtration rate (both P<0.0001). Following intervention, placebo and nifedipine did not affect plasma and urine ELDP or plasma CT-proET-1. Sitaxentan increased both plasma ELDP and CT-proET-1 (baseline versus week 6±SEM: ELDP, 11.8±0.5 versus 13.4±0.6 fmol/mL; CT-proET-1, 20.5±1.2 versus 23.3±1.5 fmol/mL; both P<0.0001). Plasma ET-1 was unaffected by any treatment. Following sitaxentan, plasma ELDP and CT-proET-1 correlated negatively with 24-hour urinary sodium excretion.ELDP and CT-proET-1 increase in CKD and thus are potentially useful biomarkers of renal injury. Increases in response to endothelin A antagonism may reflect EDN1 upregulation, which may partly explain fluid retention with these agents.URL: www.clinicalTrials.gov Unique identifier: NCT00810732.

SUBMITTER: Dhaun N 

PROVIDER: S-EPMC4392442 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.

Dhaun Neeraj N   Yuzugulen Jale J   Kimmitt Robert A RA   Wood Elizabeth G EG   Chariyavilaskul Pajaree P   MacIntyre Iain M IM   Goddard Jane J   Webb David J DJ   Corder Roger R  

Journal of the American Heart Association 20150323 3


<h4>Background</h4>Endothelin 1 (ET-1) contributes to chronic kidney disease (CKD) development and progression, and endothelin receptor antagonists are being investigated as a novel therapy for CKD. The proET-1 peptides, endothelin-like domain peptide (ELDP) and C-terminal pro-ET-1 (CT-proET-1), are both potential biomarkers of CKD and response to therapy with endothelin antagonists.<h4>Methods and results</h4>We assessed plasma and urine ELDP and plasma CT-proET-1 in CKD patients with minimal c  ...[more]

Similar Datasets

| S-EPMC4143458 | biostudies-literature
| S-EPMC7151483 | biostudies-literature
| S-EPMC10790009 | biostudies-literature
| S-EPMC3042192 | biostudies-literature
| S-EPMC1768938 | biostudies-literature
| S-EPMC10198578 | biostudies-literature
| S-EPMC2711758 | biostudies-literature
| S-EPMC9904337 | biostudies-literature
| S-EPMC4246009 | biostudies-literature
| S-EPMC3537212 | biostudies-literature